Tag: CIRSE

Reaction to the Katsanos et al meta-analysis

Internal BIBA MedTech data show that perceptions on paclitaxel devices have shifted considerably in the twelve months that have elapsed since Konstantinos Katsanos (Patras,...

Experts discuss latest results from EFFPAC and TINTIN trials presented at...

NOTE: ONLY intended for healthcare professionals outside of the USA. Ulf Teichgräber (Jena, Germany) and Koen Deloose (Dendermonde, Belgium) discuss the 24-month results of the...
CIRSE

CIRSE updates position on paclitaxel use in peripheral arteries

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has released a statement on the use of paclitaxel-coated balloons and stents in the treatment...

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
BIBLIOS

Luminor drug-coated balloon receives Canadian Medical Device Licence

iVascular has announced that its Luminor 14m peripheral balloon catheter with paclitaxel elution has received the Canadian Medical Device Licence (MDL). Luminor 14m is a...

Data from multiple studies support concept of low metal burden therapies...

Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates, according to results from various Biotronik studies...

Luminor EffPAC study shows efficacy at six months

Data have been announced demonstrating the efficacy of iVascular’s Luminor drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) at six months. The...

Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation

The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...

Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent

The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...